REG - Deltex Med Grp PLC - Grant of options

Deltex MedicalAnnouncement

17/02/2022 16:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220217:nRSQ0518Ca&default-theme=true

RNS Number : 0518C  Deltex Medical Group PLC  17 February 2022

17 February, 2022

 

Deltex Medical Group plc

("Deltex Medical" or the "Group")

Grant of options

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler
Monitoring ("ODM"), announces that yesterday, 16 February 2022, the Board
approved the issue of share options to Andy Mears, Chief Executive Officer and
Natalie Wettler, Group Finance Director, under the Company's 2003 Share Option
Scheme (the "EMI Share Scheme").

 

Employee Share Option Scheme

 

In accordance with the Company's Renumeration Policy the Board has approved
the issue of 15,000,000 share options to Andy Mears, Chief Executive and
8,500,000 share options to Natalie Wettler, Group Finance Director. The
exercise price for these options is 1.35 pence per share, the closing price on
16 February 2022. These share options will vest three years after award,
subject to performance conditions based on achieving certain specified
earnings targets, or in the event of a change in control of the Company.

 

Confirmation of Directors' interests in share options

 

Following the grant of EMI options above, the options held by Directors are
shown below:

 

Executive Director      2011 Executive Share Scheme     2003 EMI
Share Scheme     Total

 
Number
Number                Number

 

Andy Mears
150,000
25,000,000                  25,150,000

 

Natalie Wettler
-
11,250,000                  11,250,000

 

 

For further information, please contact:

 

 Deltex Medical Group plc                                        01243 774 837

 Nigel Keen, Chairman                                             investorinfo@Deltexmedical.com (mailto:investorinfo@Fitbitmedical.com)
 Andy Mears, Chief Executive
 Natalie Wettler, Group Finance Director

 Arden Partners plc                                              020 7614 5900
 Paul Shackleton (Corporate Finance)

 Simon Johnson (Corporate Broking)

 Joint Broker
 Turner Pope Investments (TPI) Ltd                               0203 657 0050
 Andy Thacker                                                     info@turnerpope.com (mailto:info@turnerpope.com)

 James Pope

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         a.   Andy Mears (Chief Executive)

                                                                   b.   Natalie Wettler (Group Finance Director)

 2    Reason for the notification
 a)   Position/status                                              See 1 a) above
 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Deltex Medical Group plc
 b)   LEI                                                          213800XN34P6LI8J6M39
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Issue of share options

       Identification code

                                                                   Identification code (ISIN) for Deltex Medical Group plc ordinary shares:
                                                                   GB0059337583

 b)   Nature of the transaction                                    Issue of options
 c)   Price(s) and volume(s)                                        Issue of share options

                                                                   a.   23,500,000

 d)   Aggregated information

      - Aggregated volume                                          23,500,000

      - Price                                                      Exercisable at 1.35 pence
 e)   Date of the transaction                                      17.02.22
 f)   Place of the transaction                                     Outside a trading venue

 

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies,
which are primarily used in critical care and general surgical procedures.
Deltex Medical's proprietary oesophageal Doppler monitoring (TrueVue Doppler)
measures blood flow velocity in the central circulation in real time. The
technology generates a low-frequency ultrasound signal which is highly
sensitive to changes in blood flow and measures such changes in 'real time'.
Deltex Medical is the only company in the enhanced haemodynamic monitoring
space to have built a robust and credible evidence base demonstrating both the
clinical and economic benefits of its core technology: TrueVue Doppler. This
technology has been proven in a wide range of clinical trials to reduce
complications suffered by patients after surgery and consequently can save
hospitals money.

 

Clinicians would like to be able to monitor the haemodynamic status of awake
patients not only in the operating room and intensive care departments.  Our
R&D programmes will provide the capability for Deltex Medical devices to
be used in A&E, including, for example, for the rapid detection of sepsis,
as well as on lower acuity wards or outside the hospital setting.

 

Deltex Medical is designing the next generation of non-invasive Doppler
ultrasound devices that will be released onto the TrueVue platform and will
accurately measure a non-sedated patient's haemodynamic status anywhere within
the hospital and not just for elective surgical patients.

 

 

 

Group goal

Haemodynamic management is now becoming widely accepted as a vital part of the
anaesthesia protocols for surgical patients, as well as treating ventilated
intensive care patients, including ventilated COVID-19 patients. There is also
a desire to start measuring haemodynamics on awake patients outside of the
operating room or intensive care departments, such as in lower acuity units or
in A&E. Our R&D programmes are targeting these broader applications.
Consequently, the Group's focus is on maximising value from the opportunities
associated with: the COVID-19 pandemic; the elective surgery backlog; the
risks associated with sepsis; awake patients and the higher profile of
haemodynamic monitoring which has arisen from recent consolidation in the
sector.

 

The Group aims to provide clinicians with a modern, next generation, single
'haemodynamic workstation' platform which offers them a range of technologies
from simple to sophisticated to be deployed according to the patient's
clinical condition as well as the skill and expertise of the user. Doing this
will enable the Group to partner with healthcare providers to support modern
haemodynamic management across the whole hospital.

 

The Group is currently in the implementation phase of achieving this goal in a
number of territories worldwide, operating directly in the UK and the USA, and
via agreements with approximately 40 distributors overseas.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFEEFAIDLIF